KRAS and neoplasm: In summary, the combination of KRAS G12C inhibitors and anti-PD-1 therapy demonstrated robust synergistic anti-tumor effects in preclinical studies, particularly in immunologically active tumors, by remodeling the tumor microenvironment to achieve durable tumor clearance and establish adaptive immune memory.